These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 17982881)

  • 21. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
    Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
    Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal models of Parkinson's disease: similarities and differences between the disease and models.
    Hattori N; Sato S
    Neuropathology; 2007 Oct; 27(5):479-83. PubMed ID: 18018484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
    Conn KJ; Gao W; McKee A; Lan MS; Ullman MD; Eisenhauer PB; Fine RE; Wells JM
    Brain Res; 2004 Oct; 1022(1-2):164-72. PubMed ID: 15353226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective loss of dopaminergic neurons and formation of Lewy body-like aggregations in alpha-synuclein transgenic fly neuronal cultures.
    Park SS; Lee D
    Eur J Neurosci; 2006 Jun; 23(11):2908-14. PubMed ID: 16819979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages.
    Nuber S; Petrasch-Parwez E; Arias-Carrión O; Koch L; Kohl Z; Schneider J; Calaminus C; Dermietzel R; Samarina A; Boy J; Nguyen HP; Teismann P; Velavan TP; Kahle PJ; von Hörsten S; Fendt M; Krüger R; Riess O
    Neurobiol Dis; 2011 Nov; 44(2):192-204. PubMed ID: 21767644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
    Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
    Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
    Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
    Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
    J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V; Cannon JR; Greenamyre JT
    J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism.
    Liu Z; Yu Y; Li X; Ross CA; Smith WW
    Pharmacol Res; 2011 May; 63(5):439-44. PubMed ID: 21237271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the pathogenetic mechanisms underlying Parkinson's disease in medaka fish.
    Matsui H; Uemura N; Yamakado H; Takeda S; Takahashi R
    J Parkinsons Dis; 2014; 4(2):301-10. PubMed ID: 24366926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genes, proteins, and neurotoxins involved in Parkinson's disease.
    von Bohlen und Halbach O; Schober A; Krieglstein K
    Prog Neurobiol; 2004 Jun; 73(3):151-77. PubMed ID: 15236834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Synuclein and Parkinsonism: Updates and Future Perspectives.
    Rosborough K; Patel N; Kalia LV
    Curr Neurol Neurosci Rep; 2017 Apr; 17(4):31. PubMed ID: 28324300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Spillantini MG; Goedert M
    Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
    Yun SP; Kim D; Kim S; Kim S; Karuppagounder SS; Kwon SH; Lee S; Kam TI; Lee S; Ham S; Park JH; Dawson VL; Dawson TM; Lee Y; Ko HS
    Mol Neurodegener; 2018 Jan; 13(1):1. PubMed ID: 29310663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.